LOS ANGELES AACR IO 2025 At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented…
Browsing: Immunotherapy
Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s…
Dr. Omid Hamid from The Angeles Clinic goes over his favorite presentations coming up at ASCO 2024. Should these be…
By. Anusha Kalbasi, MDDate. 11/22/2023In a recent discussion on adoptive T cell therapies for solid tumors, Anusha Kalbasi, MD, provided…
By. Bridget Keenan, MDDate. 11/22/2023Bridget Keenan, MD, discusses the tumor microenvironment (TME) and its crucial role in cancer immunotherapy responses.…
By. Anna M. Wu, MD, PhDDate. 11/21/2023Anna M. Wu, MD, PhD, discussed the use of immunotherapy in patients who underwent…
By. Kim Margolin, MDDate. 11/17/2023In the field of cancer immunotherapy, Kim Margolin, MD, provides insights into the interplay between the…
By. Mohamed H. Derbala, MDDate. October 31, 2023Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD…
GeoVax, a pioneering healthcare company, has developed a groundbreaking product known as GADEPTIN. GADEPTIN is a cutting-edge therapy designed to…
Timothy Looney, PhD – Senior Director, Immunology and Bioinformatics at Singular Genomics By: Timothy Looney, PhD Date: 9/12/2023 The topic…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in…
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics By Jeff Liter, MBS, CEO of Luminary…
PRO in Pts With Rare Cancers: Pembrolizumab [2022] Â Patient reported Outcome (PRO) in patients with rare cancers (rare diseases)…
Follow real-world patients on their cancer journeys as they and their multidisciplinary clinical teams navigate barriers to receiving treatment with…
EXUMA Biotech’s VP of Oncology R&D, Dr. Sid Kerkar, Reveals Preclinical Data From Its Subcutaneous CAR-TaNK And In Vivo CAR…
Xianxin Hua, MD, Ph.D., Professor of Cancer Biology at the Abramson Cancer Research Institute, Department of Cancer Biology at the…
Xianxin Hua, MD, Ph.D., Professor of Cancer Biology at the Abramson Cancer Research Institute, Department of Cancer Biology at the…
Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. In this video,…
Mehmet Altan, MD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. In this video,…
Rebecca Harrison, MD, Assistant Professor of Neuro-Oncology at MD Anderson and is now a Clinical Associate Professor BC Cancer the…
Rebecca Harrison, MD, Assistant Professor of Neuro-Oncology at MD Anderson and is now a Clinical Associate Professor BC Cancer the…
Nazanin Majd, MD, Ph.D., BS, Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine at The University of Texas MD…
Nazanin Majd, MD, Ph.D., BS, Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine at The University of Texas MD…
Augusto Villanueva, MD, Ph.D., Associate Professor, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai (NY).…
Augusto Villanueva, MD, Ph.D., Associate Professor, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai (NY).…
Peter Kim, MD, Associate Professor, Department of Cardiology, Division of Internal Medicine at MD Anderson Cancer Center. In this video,…
Bettzy Stephen, MBBS, MPH, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. In this interview,…
Bettzy Stephen, MBBS, MPH, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. In this interview,…
Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers…
Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers…
Yeonjoo Choi, MD from The Catholic University of Korea Incheon St. Mary’s Hospital speaks about T-cell Agonists In Cancer Immunotherapy.Link…
Hosts Jack West & Charu Aggarwal speak with immunotherapy expert Dr. Patrick Forde about unique advantages of the pre-operative platform…
Yeonjoo Choi, MD from The Catholic University of Korea Incheon St. Mary’s Hospital speaks about T-cell Agonists In Cancer Immunotherapy.Link…
Coya Tapia, MD, Ph.D., Surgical and Molecular Pathologist speaks about Decrease in tumor content assessed in biopsies is associated with…
Frederick L. Locke, MD from H. Lee Moffitt Cancer Center and Research Institute speaks about the Society for Immunotherapy of…
Synopsis: Â The most common symptom of cancer and its treatments is fatigue. In patients with chronic fatigue syndrome and…
Geoffrey M. Lowman, Ph.D. from Thermo Fisher Scientific discusses Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon…
Tito R. Mendoza, Ph.D., MS, MEd from The University of Texas MD Anderson Cancer Center discusses Evaluating the psychometric properties…
Daniel Catenacci, MD of the University of Chicago Medicine discusses Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its…
Jacob Adashek, DO of The University of South Florida and H. Lee Moffitt Cancer Center & Research Institute discusses the…
Jennifer Baker Flechtner, Ph.D. – Genocea Biosciences Inc’s Chief Scientific Officer discusses Genocea to Present Data that Reveal New Understanding…
Sigrun Hallmeyer, MD at ACCC discusses Immuno-Oncology and What Lies Ahead
Jacob J. Adashek, DO of Moffit Cancer Center gives an overview from ASCO 2020 the abstract entitled Targetable immune checkpoint…
Jared Gollob Chief Medical Officer @KymeraTx shares common questions he gets from colleagues such as “What’s Advantage of IRAK 4…
Jared Gollob @JaredGollob @KymeraTx gives an overview of a poster presented at AACR 2020 IRAKIMiD Degrader Program and Present Preclinical…
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…
John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…
Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Juan Carlos Varela, MD – AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune…
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses – Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults…
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews explains immunosuppression in tumors overall in the study. ______________ An active immune…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews answers what the effects are in activation for identifying molecular pathways that…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews discusses identifying molecular pathways that control immunosuppression in tumors. ______________ An active…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio discusses the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase…
Adult cancer patients reported better physical and social function after undergoing CAR-T therapy Adult lymphoma patients whose disease was effectively…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
GRACE is excited to bring to our Spanish speaking community information on Cancer Basics.Our friend and partner, Narjust (N.J.) Duma,…
Betty Hamilton, MD of @ClevelandClinic discusses the post-transplant work statue of young adult survivors of allogeneic hematopoietic cell transplant.
Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 immunotherapy, in…
Chadi Nabhan, MD MBA of Aptitude Health discusses potential of biosimilars in treatment of blood cancer.
Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy…
Robert Rifkin, MD of @TheUSONetwork discusses the Lyra study.
Jan Hillson, MD of @AlpineImmuneSci disucsses ALPN-101.
Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial…
Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Â Annual Meeting &…
Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read…
Mark Sellmyer, MD, PhD @sellmyerlab of @PennMedicine explains how CAR-T cell imaging markers will affect treatment and clinicians. ___________ Read…
Mark Sellmyer, Md, PhD @sellmyerlab of @PennMedicine answers how sensitive is this technology? ___________ Read here:Â https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php
Mark Sellmyer, MD, PhD sellmyerlab of @PennMedicine discusses to monitor cancer therapy, researchers tag CAR-T cells with imaging markers. ___________…
Daniel M. Rotroff, PhD of @CleClinicMD answers will this affect clinicians and treatment today on anti-PD-1/PD-L1 antibody immunotherapy. _________ Read…
Daniel M. Rotroff, PhD of @CleClinicMD answers commonly asked questions to anti-PD-1/PD-L1 antibody immunotherapy. _________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712
Daniel M. Rotroff, PhD of @CleClinicMD discusses the response to anti-PD-1/PD-L1 antibody immunotherapy. __________ Read here:Â https://ascopubs.org/doi/full/10.1200/JCO.19.01712
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study–Expansion cohort in head and neck squamous cell carcinoma…
Alena Gros of @VHIO answers commonly asked questions regarding the development of cell therapies for non-responders to current immunotherapies: can…
Alena Gros of @VHIO explains driving the development of cell therapies for non-responders to current immunotherapies. __________ Research conducted by…
Research conducted by VHIO’s Alena Gros suggests a modern, less intrusive approach to detecting killer T lymphocytes in patients with…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine answer how it is different…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine discuss an algorithm personalizes which…
When tumor cells expand, tens of thousands of genetic mutations are often spawned. It’s like finding a few needles in…
New multi-pronged strategy for treating advanced breast cancer earns Breakthrough Award Multifaceted approach combines 3 complementary immunotherapy strategies Two clinical…
Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. This video series presents IMPRES and…
Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology elaborates on the…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology provides some…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses how…
Elad Sharon MD @EladSharonMD Of The National Cancer Institute Discusses Pembrolizumab Trial & Broadening Eligibility For HIV Patients: Patients With…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival,…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses OSE Immunotherapeutics: French Company Based In Paris Focusing On How To Prolong…
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study: Looking At Tumor Aggression After Treatment, Up To 30 Month Clinical…
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study Questions: Why Not Use This Treatment In Earlier Stage Or Even…
Elizabeth Buchbinder MD Of DFCI Discusses SITC Advances In Cancer Immunotherapy: Great Opportunity For Clinicians To Learn About All The…
GRACE – Global Resource for Advancing Cancer Education Published on Jan 15, 2016 Terrie Schmith, a stage IV melanoma survivor,…
GRACE – Global Resource for Advancing Cancer Education Published on Jan 18, 2016 Dr. James Gulley, National Cancer Institute, discusses…
Dr. Ben Levy discusses two trials that are trying to determine if Immunotherapy can help lung cancer patients with earlier…
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and…
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon,…
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used…
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a…
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies…
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who…
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr.…
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of “pseudoprogression”.
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Should Patients In The 1st Line Setting Should Receive…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Aimwithimmunotherapy.org And The Various Resources The Site Provides For Patients And…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Whats Next With Aimwithimmunotherapy.org. For More Info Visit: Aimwithimmunotherapy.org
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Benefits Of Aimwithimmunotherapy.org And The Various Resources It Provides For Patients…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Assessment & Education Regarding (irAEs). For More Info Visit: Aimwithimmunotherapy.org
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the…
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific…
Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Protein Biomarkers, PD-L1, & Multifactorial. At the Seventeenth International Kidney Cancer…
Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Is The Secreted Variant Of PD-L1 A Systemic Immunosuppressant. At the…
Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Data Regarding A Splice Variant Of PD-L1. At the Seventeenth International…
Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses VEGF Plus Radium…
Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Treating Patients With…
Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Study Involving VEGF-Targeted…
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Making Immunotherapy Work Better For Kidney Cancer. At the Seventeenth…
Edward Copelan, MD, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses Molecular Profiling Of Patients. At…
Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses Clinical Studies Examining…
Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses Improvements To Turn Around Time With CAR-T Therapies. At The…
David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Thoughts On The Daratumamab Studies. At The…
Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses The Development Of LCAR-B38M. At The 60th ASH Annual Meeting…
Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Management Of Common…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Will CAR-T Therapies Be Expanded Into Solid Tumors. At The…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Aaron Gerds, M.D., M.S. assistant professor of medicine in the Hematology and Medical Oncology department at the Cleveland Clinic Taussig…
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage…
David Peereboom, M.D., Cleveland Clinic Discusses The Future Of Treating Glioblastoma. At ESMO Oncology Conference – Munich, Germany On October…
David Peereboom, M.D., Cleveland Clinic Discusses SL-701 Availability. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
David Peereboom, M.D., Cleveland Clinic Discusses New Plans With SL-701 Drug. At ESMO Oncology Conference – Munich, Germany On October…
David Peereboom, M.D., Cleveland Clinic Discusses How SL-701 Was Generated. At ESMO Oncology Conference – Munich, Germany On October 19,…
David Peereboom, MD, Cleveland Clinic Discusses SL-701 Phase Two Trial Study Results. At ESMO Oncology Conference – Munich, Germany On…
As chimeric antigen receptor (CAR) T-cell therapies are patient-specific, this novel treatment type poses unique challenges. From the British Oncology…
VXM01 is an orally-administered vaccine that elicits a systemic T-cell response targeting VEGFR-2. Here, Wolfgang Wick, MD, from the German…
One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo…
Immunotherapy has been making rapid advancements as of late, especially the area of CAR T-cell therapy. Howard Burris, MD, FACP,…
Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after…
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks about prostvac, a novel…
In this interview, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the results of the Phase…
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks to us about the…
David I. Quinn, MD, explains his thoughts on 2nd line therapy options following I-O failure 2018 Annual Meeting.
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients…
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR…
Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the…
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that…
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a…
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation…
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of…
Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung…
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to…
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to…